Search research articles
Contact Us
Filters
Showing results (101-110 of 114) with videos related to
Page
of 12
Sort By:
The Journal of Infectious Diseases
|
December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines
Gregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 22, 2020
Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells
Patrick A Paez, Motunrayo Kolawole, Marcela T Taruselli, et al.
Nature Communications
|
November 28, 2024
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
Maria P Lemos, Rena D Astronomo, Yunda Huang, et al.
Journal of Clinical Pharmacology
|
June 9, 2025
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIV
Yunda Huang, Lily Zhang, Maria P Lemos, et al.
The Lancet. HIV
|
November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial
Susan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
The Lancet. HIV
|
October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)
Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
BMC Immunology
|
February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Ebiomedicine
|
June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
Yunda Huang, Lily Zhang, Huub Gelderblom, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 114) with videos related to
Sort By:
Page
of 12
The Journal of Infectious Diseases
|
December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines
Gregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 22, 2020
Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells
Patrick A Paez, Motunrayo Kolawole, Marcela T Taruselli, et al.
Nature Communications
|
November 28, 2024
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosa
Maria P Lemos, Rena D Astronomo, Yunda Huang, et al.
Journal of Clinical Pharmacology
|
June 9, 2025
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIV
Yunda Huang, Lily Zhang, Maria P Lemos, et al.
The Lancet. HIV
|
November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial
Susan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
The Lancet. HIV
|
October 6, 2023
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
Magdalena E Sobieszczyk, Sharon Mannheimer, Carmen A Paez, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)
Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
The Lancet. HIV
|
December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
BMC Immunology
|
February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Tariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
Ebiomedicine
|
June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
Yunda Huang, Lily Zhang, Huub Gelderblom, et al.
Page
of 12